Why insider trading matters?

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

- Peter Lynch
Fulcrum Therapeutics, Inc. (FULC)
Sector: Healthcare; Industry: Biotechnology

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. The company is also discovering drug targets for the treatments of duchenne muscular dystrophy, friedreich ataxia, myotonic dystrophy 1, and a-synucleinopathies, as well as neurological and pulmonary diseases. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-03-16 Gould Robert J Director Sell 10,000 $12.16 $121,578 No
2021-02-22 Thomson Peter G. VP Finance & Accounting Sell 5,000 $14.72 $73,582 Yes
2021-02-16 Gould Robert J Director Sell 8,215 $14.27 $117,197 No
2021-01-21 Thomson Peter G. VP Finance & Accounting Sell 6,607 $14.00 $92,498 No
2021-01-20 Gould Robert J Director Sell 10,000 $12.08 $120,826 No
2020-07-08 Wallace Owen B. Chief Scientific Officer Sell 2,951 $20.00 $59,020 Yes
2020-07-08 Gould Robert J Director Sell 2,500 $20.00 $50,000 No
2020-07-01 Cadavid Diego SVP Clinical Development Sell 1,071 $18.30 $19,599 No
2020-06-30 Wallace Owen B. Chief Scientific Officer Sell 141 $20.00 $2,820 Yes
2020-06-25 Cadavid Diego SVP Clinical Development Sell 1,459 $22.00 $32,098 Yes
2020-06-25 Gould Robert J Director Sell 2,500 $20.80 $51,992 No
2020-06-10 Cadavid Diego SVP Clinical Development Sell 401 $22.00 $8,822 Yes
2020-06-09 Gould Robert J Director Sell 156 $20.00 $3,120 No
2020-06-05 Gould Robert J Director Sell 3,433 $20.17 $69,251 No
2020-06-05 Cadavid Diego SVP Clinical Development Sell 677 $20.14 $13,632 Yes
2020-06-04 Gould Robert J Director Sell 2,800 $20.09 $56,250 No
2020-06-03 Cadavid Diego SVP Clinical Development Sell 383 $20.16 $7,720 Yes
2020-06-02 Gould Robert J Director Sell 2,802 $20.00 $56,040 No
2020-05-29 Cadavid Diego SVP Clinical Development Sell 800 $20.01 $16,007 Yes
2020-05-29 Gould Robert J Director Sell 3,309 $20.04 $66,302 No
2020-05-28 Wallace Owen B. Chief Scientific Officer Sell 2,232 $20.00 $44,640 Yes
2020-05-27 Wallace Owen B. Chief Scientific Officer Sell 448 $20.00 $8,960 Yes
2020-05-26 Wallace Owen B. Chief Scientific Officer Sell 412 $20.00 $8,240 Yes
2020-05-26 Gould Robert J Director Sell 2,500 $20.00 $50,000 No
2020-05-12 Cadavid Diego SVP Clinical Development Sell 1,860 $18.00 $33,480 Yes
2020-05-11 Thomson Peter G. VP Finance & Accounting Sell 7,500 $16.00 $120,000 No
2020-03-02 Cadavid Diego SVP Clinical Development Sell 2,143 $17.38 $37,255 No
2020-02-24 Thomson Peter G. VP Finance & Accounting Sell 5,000 $16.83 $84,153 No
2020-02-19 Gould Robert J See Remarks Sell 2,500 $20.00 $50,000 No
2020-02-19 Wallace Owen B. Chief Scientific Officer Sell 6,088 $20.00 $121,760 Yes

Insider Smart

Edesa Biotech, Inc. (EDSA) - President and CEO bought shares of EDSA in late May around $3, two weeks after their purchase, the stock jump to $9, very well timed buy.

Insider Smart

ROYAL CARIBBEAN CRUISES (RCL) - Thompson Donald, Director of RCL feels safe and made a move. The only insiders bought RCL post crash.